Sinovac Zhongwei relied on vaccines to make a profit or more than 80 billion last year, how did Sino

Sinovac's main way of making profits is to supply vaccines to many countries.

According to the specific profitability announced by relevant companies, Sinovac Zhongwei Company accounts for a large proportion, on the one hand, because the company has obvious advantages in the field of new crown vaccines and has obtained marketing licenses in many countries and regions. On the other hand, the company has established partnerships with several countries, resulting in 2.8 billion doses of vaccines worldwide.

Since the emergence of confirmed cases of COVID-19 in several countries, many countries have sought COVID vaccines. While some countries have adopted very different approaches to vaccination, many are eager to get vaccinated. Since it is difficult for some countries to produce and develop new crown vaccines in the first time, Sinovac has become a partner of many countries.

COVID vaccine production technology and R&D technology have never been a simple concept, but require a lot of time and effort from pharmaceutical companies. Increasing technology research and development has become the development goal of Sinovac Zhongwei Company, and the company has a particularly obvious technical advantage when the technology of developing new crown pneumonia vaccines continues to make breakthroughs. Not only can we provide COVID vaccines directly to multiple countries, but we can also enter into technical cooperation with many companies around the world.

Over time, the company's popularity around the world has become more and more popular, not only recognized by residents all over the world, but also the company's profitability has been successfully increased.

In general, Chinese pharmaceutical companies are showing a steady upward trend, especially a number of vaccine manufacturers led by Sinovac Zhongwei. They not only show the comprehensive strength of China's pharmaceutical enterprises, but also reflect the continuous improvement of China's medical technology. What's more, domestic residents are vaccinated free of charge, reducing residents' spending on vaccination, and protecting the lives of the people.

Sell these vaccines to other countries, make money through their own technology to invent their own patents, sell their own patents to other countries, and create patents and copyrights.

Sinovac makes money by developing and producing vaccines, which are the company's main business, and the supply of vaccines outstrips supply.

Although Sinovac's vaccine is free, he was still able to make a profit of more than 80 billion through the support of some welfare lotteries, as well as the support of the state.

Beijing Sinovac and Juqiaotan Beijing Sinovac Zhongwei new crown vaccine are the same, but everyone has a different abbreviation and name.

Beijing Sinovac new crown vaccine and Beijing biological new crown vaccine are approved by the State Food and Drug Administration for production and marketing, and their safety and efficacy are supported by data, and the effect of the two vaccines is trustworthy. In case of special circumstances such as the vaccine cannot be continued**, the recipient is vaccinated in a different place, and the vaccination cannot be completed with the same vaccine product, the vaccine products of other manufacturers of the same type can be used to complete the vaccination.

Precautions and key points for vaccines:

You can ask the professionals of the Department of Preventive Health Care, the corresponding professionals of the Center for Disease Control and Prevention, clinicians, etc., and they will give corresponding suggestions. For example, whether hepatitis B vaccine needs to be vaccinated, you can consult a professional doctor for hepatitis B, because professional doctors are very experienced in this area; The presence of contraindications is necessary before vaccination, generally in the acute phase of the disease.

For example, if you are having fever, diarrhea, pneumonia, liver inflammation, etc., you cannot be vaccinated, and people with severe allergies to vaccine components are not suitable for vaccination. If you are unsure whether there are contraindications to the vaccine, you can inform the professional in time of your situation so that they can help evaluate whether you can get vaccinated.

The above content reference: Encyclopedia - Vaccines.

Although the founder of Sinovac Biotech is Yin Weidong, he is only ranked in the position of the second largest shareholder, and the first largest shareholder is also a very familiar SoftBank Group.

The second and third shareholders of Sinovac Biotech are the founders of Sinovac Biotech, but in addition to these Chinese companies, the others are overseas capital institutions, and the proportion is relatively large.

Although the second and third largest shareholders are both Chinese, but if the first shareholder is a foreign-funded enterprise, is Sinovac a foreign-funded enterprise or a Chinese enterprise?

Before the outbreak of the pandemic, the company was a small one. Sinovac, as a company focusing on researching vaccines, is not optimistic about its business situation when it does not encounter emergencies, but it is the epidemic that has greatly increased the demand for vaccines, so it has also made Sinovac occupy a very important position in the medical industry.

A few years before the outbreak of the epidemic, SoftBank Group had already taken a fancy to the development of Sinovac Biotech, although SoftBank Group was not sure that Sinovac Biotech could bring huge benefits to itself, but it still invested a lot of money, and the fact is that the current development of Sinovac Biotech has indeed brought huge profits to SoftBank Group.

Although Sinovac Biotech is the majority shareholder of Japan's SoftBank Group, howeverSinovac Biotech is a Chinese company, mainly because the main controller of Sinovac Biotech is Chinese.

Moreover, the headquarters of Sinovac Biotech is still located on the territory of China, plus Sinovac Biotech's vaccines, the vast majority of which are only for Chinese, and foreign people want to be vaccinated with China's vaccines, they can only be through the **** way, so it can be seen that Sinovac Biotech is a local enterprise.

Half of it, because this company is a business run in China, and it is also relatively good.

It is not a Chinese enterprise, it is a joint-stock ****, because this enterprise is a cooperation between China and foreign countries, and China's shares are still very small.

Although Sinovac's major shareholder is foreign capital, it is an authentic Chinese company, and during the epidemic, it has developed a vaccine, and the technology is quite excellent.

Because the free vaccines that we often talk about are actually mainly centralized vaccines, and our country is also paying for everyone's vaccination.

Whenever we mention vaccinations and nucleic acid tests, the first thing that comes to our mind is that neither of these services costs money. However, in fact, both the new crown vaccine and nucleic acid test themselves require certain medical costs, and the relevant vaccines we often use are also specially researched by pharmaceutical companies. For us ordinary people, every shot of vaccine and nucleic acid detection reagent we use comes from the national centralized procurement, and we have indeed enjoyed the corresponding benefits.

Sinovac's profit in 2021 may exceed 80 billion yuan.

The free vaccine itself is not free.

We need to cherish hard-won vaccines and nucleic acid detection reagents even more.

Ordinary people don't have to spend money, but the state spends a lot of money to buy it, and the state is willing to support such enterprises that contribute to the country, and these companies can also sell vaccines to other countries and make a lot of money.

This is mainly because of state procurement, vaccine exports, and vaccine donation subsidies, so it will lead to free vaccination and make money.

The money for these vaccines is paid by the state, so that how many vaccines people receive, how much subsidy the state will give them, they can make money.

This epidemic is deflated a lot, people's pockets are also thick many people's pockets, some companies have seized this opportunity, and some companies have been eliminated by the times. Because of this epidemic, companies that do research and development work related to new crown vaccines, enterprises that do nucleic acid testing, and related companies that do medical isolation have all made great progressThe original volume of billions has now risen to hundreds of billions.

It is very profitable, with low cost and high profit, and it can be said that the profit of the vaccine is dozens of times better than the cost.

It's very profitable, because every year there are a lot of people in the country who want to be vaccinated, and there will be one or two consolidation injections, and the relevant departments will allocate funds to enterprises, and these vaccines will also be supported by other countries, so it is very profitable.

The free COVID vaccine for all is very profitable, and even if you don't have income elsewhere, you can make money through patent and copyright research and development and secret recipes.

The new crown vaccine is distributed for free to the Chinese people, so how does it make 50 billion? Is it export-dependent, or is it subsidized?

Sinobio is one of the equity owners of Beijing Sinovac, and based on the profit of Sinopharm in the first half of the year, we calculate that the profit of Beijing Sinovac in the first half of the year is about 50 billion yuan. Isn't the COVID vaccine free? Why does Beijing Sinovac make so much profit?

It is a national policy to vaccinate the new crown vaccine free of charge, but as a necessary cost, such as the research and development expenses of scientific researchers, the cost of raw materials for the new crown vaccine, and the production costs, etc., are all spread on the vaccine, and the agreed price is formulated by the relevant state departments. After that, the cost of the vaccine and the subsequent vaccination costs will be integrated and borne by the medical insurance** and the national treasury. That is to say, all vaccine companies, including Beijing Sinovac and Beijing Sinopharm, are not losing money to make money, they are making money, but they will not make a lot of money, after all, as Chinese companies, they are also doing what they should do.

In addition, due to the second wave of the Delta virus, the demand abroad has increased. There are also some manufacturers whose vaccines have been licensed for sale and use in other countries, that is, they can receive foreign orders, and at present, China's vaccines have been recognized by many countries, so the number of foreign orders is also very large.

In the first half of 2021, Beijing Sinopharm and Beijing Sinovac respectively entered the World Health Organization's emergency use list, and the two companies not only sold the new crown vaccine to many countries around the world, but also cooperated with some countries to set up factories to produce and sell vaccines locally. Therefore, it is not surprising that Beijing Sinopharm and Beijing Sinovac have made a lot of money, because these companies have made a lot of foreign exchange, and in any case, they have seized such opportunities by relying on their scientific and technological strength. On the other hand, medical insurance** is paid by the people who participate in medical insurance, and bears the responsibility of reimbursing medical expenses for the insured, so after the national vaccination, the medical insurance** in some areas may be insufficient.

In this case, the state treasury will allocate funds to subsidize it. From this point of view, Sinovac's revenue and profit are also partly financed.

Although the new crown vaccine is free, in the process of production and research and development, the state will give a large-scale amount of subsidies, and after the production of the vaccine, the company's market value will rise to a certain extent, and the market is very good, so it can also have a very good profit.

This is because in the production of vaccines, the state will carry out corresponding subsidies according to a certain amount, and the relevant units will also carry out comprehensive subsidies, and in the process of production and research and development, the company's market value will rise to varying degrees.

In fact, behind the free vaccination of the whole people, is the power of the national finance, China's ** to Sinovac collective procurement, in order to ensure the profitability of the enterprise at the same time, ** will also reconcile and negotiate procurement** to reach the appropriate level, medical insurance ** and ** finance to bear the cost of our vaccine, enterprises want to produce marketable products, it is inseparable from the support.

Because everybody has to get the Covid vaccine, and more than once. So the profit is very large. Recently, vaccines have also been sold overseas.

Sinovac has been a major vaccine developer for a long time last year. Although the vaccine is free for all, this cost has been deducted from the medical insurance**.